Across TCGA pan-cancer cohorts, CALR Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CALR data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CALR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CALR expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
OV, UCEC, and SKCM are the cancer types where CALR Mutation most reproducibly stratifies survival.